• 1
    Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol 2004; 137: 496503.
  • 2
    Green WR, Wilson DJ. Choroidal neovascularization. Ophthalmology 1986; 93: 116976.
  • 3
    Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102: 16402.
  • 4
    Spaide RF. Choroidal neovascularization in younger patients. Curr Opin Ophthalmol 1999; 10: 17781.
  • 5
    VanNewkirk MR, Nanjan MB, Wang JJ, Mitchell P, Taylor HR, McCarty CA. The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology 2000; 107: 1593600.
  • 6
    Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 1991; 109: 110914.
  • 7
    Hawkins BS, Bressler NM, Bressler SB et al. Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST Report No. 9. Arch Ophthalmol 2004; 122: 1597611.
  • 8
    Lee YA, Ho TC, Chen MS, Yang CH, Yang CM. Photodynamic therapy combined with posterior subtenon triamcinolone acetonide injection in the treatment of choroidal neovascularization. Eye 2009; 23: 64551.
  • 9
    Ruiz-Oliva F, Cortes J. Verteporfin in Photodynamic Therapy (VIP) Study group. Ophthalmology. 2002; 109: 1043; author reply 1043; author reply 1044.
  • 10
    Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 141931.
  • 11
    Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 143244.
  • 12
    Regillo CD, Brown DM, Abraham P et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008; 145: 23948.
  • 13
    Chang LK, Spaide RF, Brue C, Freund KB, Klancnik JMJ, Slakter JS. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 2008; 126: 9415.
  • 14
    Gupta B, Elagouz M, Sivaprasad S. Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration. Eye 2010; 24: 20313.
  • 15
    Heier JS, Brown D, Ciulla T et al. Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Ophthalmology 2011; 118: 1118.
  • 16
    Sawa M, Gomi F, Tsujikawa M, Sakaguchi H, Tano Y. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks. Am J Ophthalmol 2009; 148: 584590.e2.
  • 17
    Mansour AM, Mackensen F, Arevalo JF et al. Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 2008; 146: 41016.
  • 18
    Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 2009; 93: 44851.
  • 19
    R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2010; ISBN 3-900051-07-0. Accessed January 2011. Available from:
  • 20
    Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897908.
  • 21
    Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983; 90: 9236.
  • 22
    Tabandeh H, Flynn HWJ, Scott IU et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999; 106: 20637.
  • 23
    Blinder KJ, Blumenkranz MS, Bressler NM et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial – VIP report no. 3. Ophthalmology 2003; 110: 66773.